miR‑494‑BAG‑1 axis is involved in cinobufacini‑induced cell proliferation and apoptosis in gastric cancer

Shen,Zhili; Li,Yan; Zhao,Chengcheng; Wang,Fen; Zhou,Rongping; Chen,Gang

doi:10.3892/mmr.2018.8788

miR‑494‑BAG‑1 axis is involved in cinobufacini‑induced cell proliferation and apoptosis in gastric cancer

Authors:
- Zhili Shen
- Yan Li
- Chengcheng Zhao
- Fen Wang
- Rongping Zhou
- Gang Chen
View Affiliations

Affiliations: Department of Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China, Clinical Laboratory, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China, Central Laboratory, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China
Published online on: March 20, 2018 https://doi.org/10.3892/mmr.2018.8788
Pages: 7435-7441

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cinobufacini is widely used in the treatment of advanced cancers. It has been previously reported that microRNA (miR)‑494 was upregulated in cinobufacini‑treated gastric cancer cells; however, the detailed role of miR‑494 in the anti‑tumor activity of cinobufacini is unclear. The present study aimed to clarify the function of miR‑494 in cinobufacini‑induced cell behavior changes. Cell viability and proliferation ability were investigated using a Cell Counting Kit‑8 assay. Flow cytometry was performed to investigate the apoptosis rate of gastric cancer (GC) cells. The mRNA expression levels of microRNA (miR)‑494 and BCL2 associated athanogene 1 (BAG‑1) were investigated using reverse transcription‑quantitative polymerase chain reaction, and the protein expression level of BAG‑1 was investigated using western blot assays. The results demonstrated that treatment with cinobufacini suppressed proliferation and promoted apoptosis of gastric cancer cells. miR‑494 acts as a tumor suppressor gene in gastric cancer. In cinobufacini‑treated cells, miR‑494 and BAG‑1 exhibited opposing expression trends. Furthermore, knockdown of miR‑494 in cinobufacini‑treated cells upregulated the protein expression level of BAG‑1, promoted cell proliferation and inhibited cell apoptosis. In addition, inhibition of BAG‑1 using small interfering RNA in cinobufacini‑treated cells partially abrogated the effects of miR‑494 inhibitor on cell proliferation and apoptosis. Thus, these results suggest that cinobufacini suppresses GC cells proliferation and promotes apoptosis partially through the regulation of miR‑494‑BAG‑1 axis, which may provide a novel insight into the functional mechanism of cinobufacini.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA: CA Cancer J Clin. 65:87–108. 2015.
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Qi F, Li A, Zhao L, Xu H, Inagaki Y, Wang D, Cui X, Gao B, Kokudo N, Nakata M, et al: Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol. 128:654–661. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wang D and Bi Z: Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. Tumour Biol. 35:4885–4890. 2014. View Article : Google Scholar : PubMed/NCBI
5	Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui X, Zhang L, Kokudo N, Du G and Tang W: Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells. Food Chem Toxicol. 50:295–302. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ma L, Song B, Jin H, Pi J, Liu L, Jiang J and Cai J: Cinobufacini induced MDA-MB-231 cell apoptosis-associated cell cycle arrest and cytoskeleton function. Bioorg Med Chem Lett. 22:1459–1463. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lee S, Lee Y, Choi YJ, Han KS and Chung HW: Cyto-/genotoxic effects of the ethanol extract of Chan Su, a traditional Chinese medicine, in human cancer cell lines. J Ethnopharmacol. 152:372–376. 2014. View Article : Google Scholar : PubMed/NCBI
8	Xie X, Huang X, Li J, Lv X, Huang J, Tang S and Sun Y: Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: A meta-analysis. Med Hypotheses. 81:243–250. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yang J, Zhu L, Wu Z and Wang Y: Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev (Issue 4). CD0050962013.
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	He W, Li Y, Chen X, Lu L, Tang B, Wang Z, Pan Y, Cai S, He Y and Ke Z: MiR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol. 29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
12	Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, et al: Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 7:68371–68384. 2016. View Article : Google Scholar : PubMed/NCBI
13	Song L, Liu D, Wang B, He J, Zhang S, Dai Z, Ma X and Wang X: MiR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/beta-catenin signaling pathway. Oncol Rep. 34:525–531. 2015. View Article : Google Scholar : PubMed/NCBI
14	Li N, Zhao X, Wang L, Zhang S, Cui M and He J: MiR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R. Tumour Biol. 37:7767–7776. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chen B, Hou Z, Li C and Tong Y: MiRNA-494 inhibits metastasis of cervical cancer through Pttg1. Tumour Biol. 36:7143–7149. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhou RP, Chen G, Shen ZL and Pan LQ: Cinobufacin suppresses cell proliferation via miR-494 in BGC-823 gastric cancer cells. Asian Pac J Cancer Prev. 15:1241–1245. 2014. View Article : Google Scholar : PubMed/NCBI
17	Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, Hague A, Paraskeva C and Williams AC: BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 29:849–857. 2008. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, Li A and Tang W: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ, et al: Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: A multicenter randomized controlled trial. J Integr Med. 11:90–100. 2013. View Article : Google Scholar : PubMed/NCBI
21	Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, et al: Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: A randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 107:411–416. 2012. View Article : Google Scholar : PubMed/NCBI
22	Dong J, Zhai X, Chen Z, Liu Q, Ye H, Chen W and Ling C: Treatment of huge hepatocellular carcinoma using Cinobufacini injection in transarterial chemoembolization: A retrospective study. Evid Based Complement Alternat Med: 2754542. 2016. View Article : Google Scholar
23	Chen Z, Chen HY, Lang QB, Li B, Zhai XF, Guo YY, Yue XQ and Ling CQ: Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial. Chin J Integr Med. 18:339–344. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH and Mao ZJ: Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. Complement Ther Med. 24:55–62. 2016. View Article : Google Scholar : PubMed/NCBI
25	Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wu Q, Lin WD, Liao GQ, Zhang LG, Wen SQ and Lin JY: Antiproliferative effects of cinobufacini on human hepatocellular carcinoma HepG2 cells detected by atomic force microscopy. World J Gastroenterol. 21:854–861. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yin JQ, Wen L, Wu LC, Gao ZH, Huang G, Wang J, Zou CY, Tan PX, Yong BC, Jia Q, et al: The glycogen synthase kinase-3beta/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells. Toxicol Lett. 218:129–136. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li J, Wang L, Liu Z, Zu C, Xing F, Yang P, Yang Y, Dang X and Wang K: MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9. Oncotarget. 6:26216–26229. 2015.PubMed/NCBI
29	Shrestha S, Hsu SD, Huang WY, Huang HY, Chen W, Weng SL and Huang HD: A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 3:878–888. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ni W, Chen B, Zhou G, Lu C, Xiao M, Guan C, Zhang Y, He S, Shen A and Ni R: Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. J Cell Biochem. 114:2120–2130. 2013. View Article : Google Scholar : PubMed/NCBI
31	Sun NF, Meng QY, Hu SY, Tian AL, Wang RH, Liu ZX and Xu L: Correlation between the expression of the BAG-1 gene and clinicopathologic factors in colorectal cancer. J Cancer Res Clin Oncol. 137:1419–1424. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zheng HC, Xu XY, Xing YN, Wei ZL, Takahashi H, Masuda S and Takano Y: Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas. Hum Pathol. 41:724–736. 2010. View Article : Google Scholar : PubMed/NCBI
33	Krajewska M, Turner BC, Shabaik A, Krajewski S and Reed JC: Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate. 66:801–810. 2006. View Article : Google Scholar : PubMed/NCBI